Malignant News and Research

RSS

New minimally invasive ultrasound-guided biopsy method allows improved diagnosis of endometrial disease

A procedure used in conjunction with a vaginal ultrasound might make it easier to visualize and diagnose diseases in the lining of the uterus, researchers at UT Southwestern Medical Center have found.

14 Apr 2009

Therapeutic effect of imatinib improved with addition of chloroquine

The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.

13 Apr 2009

Discovery of chemical compound that may stop deadly brain tumors

Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.

12 Apr 2009

Discovery of compound that may stop glioblastoma multiforme

12 Apr 2009

Marijuana use may increase risk of testicular cancer

Frequent and/or long-term marijuana use may significantly increase a man's risk of developing the most aggressive type of testicular cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center.

12 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Discovery of marker for colon stem cells could shed light on tumor growth

Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware, have discovered an enzyme common to both normal and malignant colon stem cells that will assist scientists searching for a cure for colon cancer.

8 Apr 2009

Deadly skin cancer now threatens women in their twenties

The deadliest form of skin cancer has now become the most common kind of cancer for women in their 20s - according to the latest figures from Cancer Research UK which launches its 2009 SunSmart campaign today.

7 Apr 2009

Avastin safe and effective at delaying tumor progression

The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

6 Apr 2009

BRAF gene mutation is a crucial skin cancer switch

Up to 70 per cent of melanoma skin cancers could be triggered by a particular genetic mutation, according to a Cancer Research UK funded study published in Cancer Cell.

6 Apr 2009

Researchers at the UJI increase the efficiency of photocatalysts used in cancer treatments

Researchers at the Universitat Jaume I (UJI) in Castellon have found porous polymeric materials that increase the efficiency of traditional photocatalysts in the treatment of cancer.

6 Apr 2009

Fluorescent cancer cells to guide brain surgeons

Gliomas are malignant brain tumors that arise from glial (supporting) cells of the brain.

5 Apr 2009

Computer based model helps tell benign and malignant breast lesions apart

Radiologists have developed a computer based model that aids them in discriminating between benign and malignant breast lesions, according to a study performed at the University Of Wisconsin School of Medicine, Madison, WI.

5 Apr 2009

Neurokinin 1 receptor may prove useful in treating deadly brain tumors

Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.

5 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009